Intra-Cellular: J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new securities filings that shed light into the back-and-forth talks behind the biggest biotech buyout of ...